Navigation Links
WuXi PharmaTech Announces Second-Quarter 2009 Results
Date:8/11/2009

865 14,279 Deferred revenue 3,837 3,373 Advanced subsidies 3,047 3,080 Other taxes payable 3,320 5,742 Other current liabilities 5,319 3,448 Liabilities of discontinued operations (Note 1) 83 1,495 Total current liabilities 97,945 58,804 Non-current liabilities: Long-term debt, excluding current portion 2,242 2,305 Advanced subsidies 1,706 1,819 Convertible notes 35,864 35,864 Other non-current liabilities 7,389 6,731 Total non-current liabilities 47,201 46,719 Total liabilities 145,146 105,523 Shareholders' equity: Ordinary shares ($0.02 par value, 5,002,500,000 authorized as of June 30, 2009 and December 31, 2008, respectively; 544,157,080 and 529,385,590 issued and outstanding as of June 30, 2009, and December 31, 2008, respectively) 10,883 10,588 Additional paid-in capital 314,329 324,629 Accumulated deficit (95,084) (121,505) Accumulated other comprehensive income 16,957 17,164 Total shareholders' equity 247,085 230,876 Total liabilities and shareholders' equity 392,231 336,399 Note 1: The biologics manufacturing operations in Philadelphia, which management decided to close in December 2008, were classified as discontinued operations. Note 2: Assets of discontinued operations included assets h
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
2. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
3. WuXi PharmaTech Receives Award from BASF
4. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
5. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
6. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
7. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
8. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
9. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
10. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
11. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... WI (PRWEB) , ... September 01, 2015 , ... In ... Venice expertly transports the reader to a not-so-distant future faced with an Ebola pandemic ... beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, and who ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, ... and pain management space join prominent academics and key investors for Neuro Advance ... Medical School in Boston. , Neuro Advance Boston focuses on the latest ...
(Date:9/1/2015)... N.C. , Sept. 1, 2015   ... to facilitating the relationship between doctors and patients, ... Durham, N.C. -based venture capital ... strength and business association with Bull City Venture ... Malik , Medfusion Founder and Executive Chairman. "Both ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... PALO ALTO, Calif., Sept. 26 Jazz,Pharmaceuticals, Inc. ... Cozadd, the,company,s Executive Chairman, will provide a corporate ... New York, NY on October 8,2007 at 8:00 ... the presentation may be accessed by visiting the,Investors ...
... announced,today that Mr. Jeffrey H. Buchalter has been ... With more than 20 years of experience in,product ... Mr. Buchalter is well poised to work with ... toward,commercializing its pipeline. "We are honored that ...
... Deal Includes up to $100MM in License Fees ... 26 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), ... with Japan Tobacco Inc. (JT) (TSE: 2914) and ... business subsidiary,under which JT and Torii will hold ...
Cached Biology Technology:Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 2Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 3Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan 4
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... "intriguing" discovery that a natural plant hormone, applied to ... The study is scheduled for the Sept. 23 issue ... , a bi-weekly publication. Jing Quan Yu and ... production for the world,s growing population. Farmers worldwide use ...
... of Standards and Technology (NIST) has demonstrated a ... elusive hazards such as concealed explosives and toxins, ... soil by wind and rain. The prototype method ... traces of these materials, which are polarlike water ...
... to be able to find explosive materials and persons ... such searches, the National Institute of Standards and Technology ... has developed a new certified reference material, Standard Reference ... and laboratory assay methods, the SRM will be helpful ...
Cached Biology News:Prototype NIST method detects and measures elusive hazards 2New NIST trace explosives standard slated for homeland security duty 2
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: